GSK Statement On FDA's Proposed Label Revisions For Some Asthma Medicines
Links shared publicly online about this topic.
- 1,368total visits
GSK Statement On FDA's Proposed Label Revisions For Some Asthma Medicines
GlaxoSmithKline (NYSE: GSK) is reviewing label changes proposed by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Adv
View full resource at medicalnewstoday.com
Tags: Asthma, Drug, FDA, GlaxoSmithKline
Most Recently Shared on February 20, 2010 at 2:06 pm By:
GSK Statement On FDA's Proposed Label Revisions For Some Asthma Medicines http://mnt.to/3xTF #asthma
GSK Statement on FDA's Proposed Label Revisions for Some Asthma Medicines - Drugs.com MedNews
drugs.com — “GlaxoSmithKline (NYSE GSK) is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting” View full resource at drugs.com
Most Recently Shared on February 20, 2010 at 12:34 pm By:
Michael Blaiss, MD Physician, Doctor, and Allergist
GSK Statement on FDA's Proposed Label Revisions for Some Asthma Medicines http://is.gd/8N3VM
Advertisement
